- Home
- LU vs BCRX Comparison
LU vs BCRX Comparison
Compare LU & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | BCRX |
|---|---|---|
| Founded | 2005 | 1986 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | LU | BCRX |
|---|---|---|
| Price | $2.26 | $9.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.82 |
| AVG Volume (30 Days) | 1.5M | ★ 4.2M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | N/A | ★ 1.21 |
| Revenue | N/A | ★ $25,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.52 | $12.55 |
| P/E Ratio | ★ N/A | $6.79 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.22 | $6.00 |
| 52 Week High | $4.57 | $11.31 |
Technical Indicators
Market Signals| Indicator | LU | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.54 | 72.16 |
| Support Level | N/A | $7.95 |
| Resistance Level | $2.77 | N/A |
| Average True Range (ATR) | 0.09 | 0.43 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 5.74 | 89.01 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.